GlassScriptPhysician profile
Steven W Kim
NPI 1003886698
$8,270.12
in general payments reported to CMS, 2019-2025
55 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $411 · 2021: $508 · 2022: $1,137 · 2023: $1,612 · 2024: $1,523 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,386 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,386.46 |
| Education | $231.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,113.49 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Celgene Corporation | $1,009.36 | 2022-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $532.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $489.21 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astellas Pharma US INC | $467.03 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Eisai INC. | $400.79 | 2019-2025 | |
| Abbvie INC. | $385.78 | 2019-2025 | |
| Pfizer INC. | $379.38 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $314.62 | 2020-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $291.57 | 2019-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $280.49 | 2019-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $246.54 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Amgen INC. | $222.79 | 2020-2025 | Blincyto, Kyprolis |
| Lilly USA, LLC | $205.01 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $158.17 | 2020-2025 | Rybrevant, Erleada, Darzalex |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $144.19 | 2024-2025 | Libtayo |
| Beigene USA, INC. | $140.14 | 2021-2023 | Brukinsa |
| Gilead Sciences, INC. | $127.17 | 2019-2025 | Trodelvy |
| Micro-Tech Endoscopy USA, INC. | $109.00 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $100.98 | 2019-2025 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $93.80 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.44 | 2022-2025 | Fruzaqla, Ninlaro |
| Genentech USA, INC. | $78.48 | 2019-2025 | Itovebi |
| Karyopharm Therapeutics INC. | $76.10 | 2024-2025 | Xpovio |
| Seagen INC. | $70.29 | 2021-2023 | Tukysa |
| Medexus Pharma, INC. | $63.33 | 2025 | Grafapex |
| Exelixis INC. | $60.87 | 2019-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $46.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.33 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $42.32 | 2024-2025 | Qinlock |
| Verastem, INC. | $41.39 | 2019-2020 | |
| Array Biopharma INC | $40.85 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $36.79 | 2019-2020 | |
| Genmab U.S., INC. | $32.50 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $31.91 | 2024-2025 | Ojjaara |
| Telix Pharmaceuticals | $29.83 | 2025 | Illuccix |
| Beone Medicines USA, INC. | $28.94 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $28.84 | 2025 | |
| Legend Biotech USA INC. | $28.48 | 2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $26.84 | 2025 | |
| Sobi, INC | $26.38 | 2025 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Springworks Therapeutics, INC. | $23.84 | 2024 | Ogsiveo |
| Tolmar, INC. | $23.49 | 2023 | |
| Rigel Pharmaceuticals, INC. | $22.06 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Clovis Oncology, INC. | $18.75 | 2020 | |
| Epizyme, INC. | $18.26 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.40 | 2025 | Ultomiris |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.